drugset / Trial / NCT07442890
A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron
Non-randomizedParallel-groupSingle-blindPrevention
Summary
This study aims to evaluate the efficacy and safety of a combination regimen based on Rolapitant Palonosetron injection for preventing nausea and vomiting induced by concurrent chemoradiotherapy in lung cancer patients. It will also analyze the differences in preventive efficacy between two combination regimens, filling the gap in antiemetic data for radiotherapy combined with moderately to highly emetogenic chemotherapy. This research will provide evidence for optimizing antiemetic strategies in patients undergoing concurrent chemoradiotherapy.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2028-04-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | 5 mg | Oral |
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
| Subject | Rolapitant | Small molecule | 218 mg | Intravenous |
| Background | Dexamethasone | Small molecule | 3.75 mg | Oral |